Resources

2020 Pharmaceutical Crystallization Summit Report 1
Crystallization technologies are bridges between drug substances (DS) and drug products (DP) enabling consistent and robust safety and efficacy profiles of small molecule based medicines.
Author: Dr. Jian Wang
Publish Date: 2020-10-18 18:01:44
A Challenging Path to Controlled Nano-API Crystallization and Isolation 2
Controlled crystallization of an API in submicron size was enabled based on an accurate solubility profile and a growth inhibition property via semi-continuous processing, to meet special formulation requirements.
Author: Don Kientzler
Publish Date: 2020-10-29 19:17:16
Addressing Bottleneck Problems in Crystallization R&D for New Drug Development 3
Diverse crystallization challenges encountered by CfPC (Center for Pharma Crystallization) and our clients will be analyzed systematically to provide insights into main bottleneck problems in today’s drug development programs.
Author: Dr. Jian Wang
Publish Date: 2020-10-28 20:09:53
Advantages of Co-precipitation Technology (CPT) Part I: Enhancement in Particle Morphology and Flow 4
Direct compression (DC) process is the preferred method for tablet production because it is both simple and energy saving.
Publish Date: 2020-11-11 18:20:52
Amorphous Solid Dispersion: Improving Dissolution Rate of Poorly Water-Soluble Drug Substance 5
Research studies show that the majority of API candidates in the development pipeline have a BCS Class II rating, which means those APIs need a solubilization strategy to promote the bioavailability to improve their chance of clinical success.
Author: Drug Product Development
Publish Date: 2020-11-11 18:15:01
Bridging the Drug Substance and Drug Product Interface 6
With the ability to develop both Drug Substance (DS) and Drug product (DP) under the same umbrella, our team enjoys a synergism absent in most CROs. The ability to bridge the DS/DP interface is a major competitive advantage, and we are able to shorten development timeline and to improve ruggedness of the DP process.
Author: Drug Product Development
Publish Date: 2020-11-05 18:53:47
Computation Assisted Solvent Selection in Crystal Form Investigation 7
Rational selection of solvents plays a critical role in solid form screening and production. On the one hand, a variety of solvents with different properties are chosen in form screening to maximize the screening space of searching for all potential solid forms because some solvents selectively favor the generation of a particular form as a result of crystallization kinetics.
Author: Dr. Shanming Kuang
Publish Date: 2020-10-17 20:02:04
Enabling Technology I.	Co-Precipitation Technology (CPT) for the Enhancement of Flowability and Bulk Density 8
Direct compression (DC) process is the preferred method for tablet production because it is both simple and energy saving.
Author: Drug Product Development
Publish Date: 2020-11-11 18:34:29
Enabling Technology II.	Dry Particle Coating for the Enhancement of  Flowability and Bulk Density 9
Many active pharmaceutical ingredients (API) exhibit deficient bulk powder properties such as poor flowability, low bulk density, high cohesion, etc.
Author: Drug Product Development
Publish Date: 2020-11-11 18:38:10
Enhance Powder Flow Density and Flow By Dry Particle Coating 10
Many active pharmaceutical ingredients (API) exhibit deficient bulk powder properties such as poor flowability, low bulk density, high cohesion, etc.
Author: Drug Product Development
Publish Date: 2020-11-11 18:29:06
Integrative Approaches to Addressing Canonical Problems in Pharmaceutical Crystallization 11
Problems associated with polymorphic instability and increasingly insoluble drug candidates represent white space to innovate novel forms and processing methods with better properties in the drug product. But the journey from identifying new solid forms to creating engineered particles with optimal formulation properties has often been too inefficient to realize this goal.
Author: Dr. William Glauser
Publish Date: 2020-10-18 10:53:47
Pharmaceutical Crystallization Support by Computational Approaches 12
Given challenges facing the pharmaceutical industry, an accelerated Drug Development greatly benefits from guidance provided by computational methods. This presentation will focus on computational support of the following important tasks related to the pharmaceutical crystallization.
Author: Dr. Yuriy A. Abramov
Publish Date: 2020-10-28 20:04:55

Resource Types

Services